You are here

Aerosolized hyaluronic acid as a treatment for emphysema

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 1R41HL068383-01
Amount: $99,409.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1 WALNUT ST BOSTON, MA 02108-3616
BOSTON, MA 02108
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JEROME CANTOR
 (718) 283-7154
 JOCANTOR@POL.NET
Business Contact
 SANTEL, DONALD J
Phone: (787) 283-7154
Email: SANTEL@MINDSPRING.COM
Research Institution
 ST. LUKE'S ROOSEVELT HOSPITAL CENTER
 
ST. LUKE'S ROOSEVELT HOSPITAL CENTER
NEW YORK, NY 12125
United States

 Nonprofit college or university
Abstract

DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease
afflicts 12-14 million people in the US and in an advanced form, emphysema,
disables 2 million and ultimately leads to death. No approved, existing
treatment can arrest emphysema's progressive destruction of the lung. Exhale
Therapeutics, Inc intends to develop and commercialize aerosolized hyaluronic
acid (HA) into the first effective therapeutic product that can preserve lung
function. The long-term objectives of the proposed project (Phases I) are: (1)
to show that aerosolized low-molecular weight HA inhaled daily protects against
lung elastic fiber injury and subsequent destruction of alveoli; and (2) to
elucidate the protective mechanism. The specific aim of Phase I is to
demonstrate that in mice exposed regularly to tobacco smoke in a chamber that
simulates cigarette smoking, daily treatment with HA administered as an aerosol
significantly reduces the severity of emphysematous damage to their lungs. Two
groups of mice will smoke, the first will receive daily treatment with HA
dissolved in distilled water, and the second will receive nebulized water only.
A comparison of the mean linear intercept of lung sections of the two groups
will provide a direct quantitative measure of the protective effect of HA.
Other semi-quantitative measures will provide supporting evidence.
PROPOSED COMMERCIAL APPLICATION:
Hyaluronic acid (HA) has the potential to become an effective therapeutic agent that can
protect lung function against the chronic destruction of alveoli in emphysema. Since no
treatment for pulmonary emphysema currently exists, proof of safety and efficacy in
humans will permit rapid commercialization. The proposed research in an animal model
will accelerate the formulation of a therapeutic product for study and use in humans.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government